Pay in 4 interest-free payments of $7.50 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
KRAS-C9 provides structure-based validation of a new allosteric regulatory site on Ras that is targetable in a mutant-specific manner
5-a]pyrimidin-3-yl]-2-methyl-
and survival
Fluid shear stress inhibits TNF-mediated JNK activation via MEK5-BMK1 in endothelial cells
GCN5 and GNAT
AZD-9291 - CAS# 1421373-65-0 0084 KRAS-C9 provides structure-based validation ofAZD 9291, CAS No. 1421373 65 0, also known as Osimertinib and Mereletinib, is a third generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors. AZD9291 is highly active in preclinical models and is well tolerated in animal models. It inhibits both activating and resistant EGFR mutations while sparing the normal form of EGFR that is
US$ 2745.00
US$ 2495.00
US$ 14250.00
US$ 75000.00
US$ 6250.00
US$ 17250.00
US$ 5750.00
US$ 2245.00
US$ 88.95
US$ 1595.00
US$ 9750.00
US$ 5400.00
US$ 6950.00